Fisher Asset Management LLC Boosts Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Fisher Asset Management LLC increased its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 26.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 848,909 shares of the company's stock after purchasing an additional 179,114 shares during the quarter. Fisher Asset Management LLC owned approximately 0.98% of IDEAYA Biosciences worth $26,893,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of IDYA. Nisa Investment Advisors LLC boosted its position in IDEAYA Biosciences by 38.4% during the second quarter. Nisa Investment Advisors LLC now owns 3,340 shares of the company's stock valued at $117,000 after acquiring an additional 927 shares during the last quarter. Quest Partners LLC acquired a new position in shares of IDEAYA Biosciences during the second quarter valued at about $41,000. Scientech Research LLC raised its holdings in shares of IDEAYA Biosciences by 362.3% during the second quarter. Scientech Research LLC now owns 27,708 shares of the company's stock valued at $973,000 after purchasing an additional 21,714 shares during the period. D. E. Shaw & Co. Inc. raised its holdings in shares of IDEAYA Biosciences by 34.4% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 884,538 shares of the company's stock worth $31,056,000 after acquiring an additional 226,514 shares during the last quarter. Finally, Envestnet Asset Management Inc. raised its holdings in shares of IDEAYA Biosciences by 24.5% in the 2nd quarter. Envestnet Asset Management Inc. now owns 104,553 shares of the company's stock worth $3,671,000 after acquiring an additional 20,607 shares during the last quarter. Institutional investors own 98.29% of the company's stock.

IDEAYA Biosciences Trading Up 0.9 %

NASDAQ IDYA opened at $26.78 on Wednesday. IDEAYA Biosciences, Inc. has a 1 year low of $25.20 and a 1 year high of $47.74. The company's 50 day simple moving average is $30.00 and its two-hundred day simple moving average is $35.54.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its earnings results on Monday, November 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.03. During the same quarter in the previous year, the firm earned ($0.46) earnings per share. As a group, research analysts predict that IDEAYA Biosciences, Inc. will post -2.46 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Leerink Partners lowered shares of IDEAYA Biosciences from an "outperform" rating to a "market perform" rating and lowered their target price for the stock from $41.00 to $27.00 in a report on Tuesday, November 5th. Oppenheimer reiterated an "outperform" rating and issued a $53.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, October 29th. Cantor Fitzgerald began coverage on shares of IDEAYA Biosciences in a research note on Tuesday, October 15th. They issued an "overweight" rating for the company. Royal Bank of Canada reiterated an "outperform" rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, September 24th. Finally, UBS Group started coverage on shares of IDEAYA Biosciences in a research note on Thursday, October 24th. They issued a "buy" rating and a $50.00 price objective for the company. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, IDEAYA Biosciences currently has a consensus rating of "Moderate Buy" and an average target price of $53.67.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.